Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:10AM ET
0.5596
Dollar change
+0.0032
Percentage change
0.58
%
IndexRUT P/E- EPS (ttm)-0.69 Insider Own5.40% Shs Outstand418.92M Perf Week-0.46%
Market Cap234.43M Forward P/E- EPS next Y-0.69 Insider Trans2.38% Shs Float396.29M Perf Month-25.51%
Income-245.97M PEG- EPS next Q-0.15 Inst Own54.83% Short Float11.54% Perf Quarter-29.68%
Sales156.31M P/S1.50 EPS this Y40.87% Inst Trans7.36% Short Ratio4.43 Perf Half Y-52.17%
Book/sh-0.41 P/B- EPS next Y-68.63% ROA-67.57% Short Interest45.75M Perf Year-61.47%
Cash/sh0.18 P/C3.08 EPS next 5Y- ROE- 52W Range0.49 - 2.13 Perf YTD-32.41%
Dividend Est.- P/FCF- EPS past 5Y13.79% ROI-556.21% 52W High-73.73% Beta1.25
Dividend TTM- Quick Ratio0.44 Sales past 5Y98.93% Gross Margin89.32% 52W Low15.38% ATR (14)0.06
Dividend Ex-Date- Current Ratio0.44 EPS Y/Y TTM11.50% Oper. Margin-102.43% RSI (14)41.37 Volatility7.23% 9.44%
Employees389 Debt/Eq- Sales Y/Y TTM59.46% Profit Margin-157.36% Recom1.20 Target Price5.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q51.04% Payout- Rel Volume0.21 Prev Close0.56
Sales Surprise78.09% EPS Surprise-143.45% Sales Q/Q195.22% EarningsMar 14 BMO Avg Volume10.34M Price0.56
SMA20-9.03% SMA50-14.04% SMA200-45.74% Trades Volume316,360 Change0.58%
Date Action Analyst Rating Change Price Target Change
Jun-06-23Initiated Robert W. Baird Outperform $8
Jun-06-23Initiated Robert W. Baird Outperform $60 → $80
Feb-28-23Resumed H.C. Wainwright Buy $8
Sep-28-22Initiated SMBC Nikko Outperform $5
Dec-16-21Initiated H.C. Wainwright Buy $12
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Mar-22-24 01:25PM
Mar-15-24 02:11PM
Mar-14-24 01:30PM
08:51AM
07:39AM
07:30AM Loading…
07:30AM
Mar-06-24 07:30AM
Mar-05-24 04:30PM
Feb-29-24 07:30AM
Feb-26-24 07:30AM
Feb-15-24 06:38PM
07:02AM
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Jan-26-24 03:57PM
07:30AM Loading…
Jan-22-24 07:30AM
Jan-05-24 04:30PM
Jan-04-24 07:30AM
Dec-24-23 09:45AM
Dec-20-23 07:30AM
Dec-11-23 07:30AM
Nov-07-23 06:55AM
06:41AM
06:30AM
Oct-26-23 09:05AM
Oct-22-23 12:00PM
Oct-21-23 04:15AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
Sep-01-23 04:30PM
08:30AM Loading…
Aug-28-23 08:30AM
07:30AM
Aug-24-23 09:54AM
Aug-23-23 02:00PM
01:16PM
08:00AM
Aug-18-23 04:27AM
Aug-17-23 10:04AM
Aug-09-23 08:30AM
Aug-08-23 10:00AM
08:19AM
07:30AM
Aug-03-23 05:25PM
Jul-28-23 07:30AM
Jul-26-23 07:30AM
Jul-20-23 07:30AM
Jul-10-23 07:58AM
Jun-30-23 11:15AM
Jun-26-23 10:15AM
Jun-06-23 07:46AM
Jun-05-23 09:49AM
07:30AM
May-25-23 07:30AM
May-10-23 06:11AM
May-09-23 07:00PM
09:15AM
08:10AM
08:00AM
May-03-23 09:08AM
Apr-26-23 10:35AM
Apr-25-23 07:30AM
Apr-24-23 07:30AM
Apr-18-23 11:20AM
Apr-17-23 01:55PM
08:47AM
07:30AM
Apr-12-23 04:30PM
Apr-04-23 03:53PM
Mar-30-23 08:41AM
Mar-27-23 03:12PM
09:45AM
Mar-23-23 12:21PM
Mar-17-23 04:31AM
Mar-14-23 04:00PM
08:45AM
07:30AM
Mar-12-23 08:29PM
Mar-11-23 11:24AM
Feb-28-23 07:30AM
07:30AM
Jan-31-23 06:20AM
Jan-26-23 07:30AM
Jan-23-23 02:33PM
07:30AM
Jan-18-23 11:11AM
Jan-10-23 08:30AM
Dec-28-22 10:39AM
Dec-21-22 10:59AM
08:30AM
Dec-19-22 12:55PM
Dec-02-22 04:47PM
Nov-17-22 08:30AM
Nov-16-22 08:30AM
Nov-14-22 08:30AM
Nov-10-22 06:02AM
Nov-08-22 02:00PM
09:25AM
08:00AM
Oct-31-22 05:50PM
Oct-26-22 10:11AM
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMEN GARO HSee RemarksFeb 15 '24Buy0.65500,000324,050625,969Feb 15 06:59 PM
WIINBERG ULFDirectorNov 15 '23Buy0.7625,00019,000124,063Nov 17 04:22 PM
AGENUS INC10% OwnerOct 16 '23Buy1.1042947221,772,863Oct 16 05:49 PM
AGENUS INC10% OwnerOct 13 '23Buy1.1019,37321,31021,772,434Oct 16 05:49 PM
AGENUS INC10% OwnerOct 12 '23Buy1.103,1733,48821,753,061Oct 16 05:49 PM
AGENUS INC10% OwnerOct 04 '23Buy1.0915,00116,38021,749,888Oct 06 04:26 PM
AGENUS INC10% OwnerAug 29 '23Buy1.5229,67845,01621,734,887Aug 31 05:53 PM
AGENUS INC10% OwnerAug 28 '23Buy1.4512,80818,57021,705,209Aug 28 05:15 PM
AGENUS INC10% OwnerAug 24 '23Buy1.54170,244262,90821,692,401Aug 28 05:15 PM
AGENUS INC10% OwnerMay 11 '23Buy1.4323,36133,34821,640,473May 12 05:18 PM
AGENUS INC10% OwnerMay 10 '23Buy1.5122,06533,29621,617,112May 12 05:18 PM
AGENUS INC10% OwnerMay 05 '23Buy0.95100,20095,10021,595,047May 05 06:00 PM
AGENUS INC10% OwnerMay 04 '23Buy1.2221,47326,24621,494,847May 05 06:00 PM
AGENUS INC10% OwnerMay 03 '23Buy1.08128,689138,84321,473,374May 05 06:00 PM